Overview
Compare with Cardio Diagnostics Holdings, Inc., Celldex Therapeutics or Q/C TECHNOLOGIES, INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Sales of goods | $0 | $0 | $0 |
| Total revenue | $0 | $0 | $0 |
| Cost of goods sold | $0 | $0 | $0 |
| Research and development | $1.5M | $3.3M | $4.0M |
| General and administrative | $2.2M | $1.0M | $4.4M |
| Total operating expenses | $3.7M | $4.3M | $8.3M |
| Loss from operations | -$3.7M | -$4.3M | -$8.3M |
| Loss on conversion of debt | $440.0K | ||
| Other income | $0 | $0 | $0 |
| Finance income | -$11.0K | $17.0K | $7.0K |
| Finance costs | -$587.0K | -$226.0K | -$58.0K |
| Operating lease interest expense | $0 | $0 | $3.0K |
| Loss before income taxes | -$4.3M | -$4.5M | -$8.8M |
| Income tax provision (recovery) | $0 | $0 | $0 |
| Net loss | -$4.3M | -$4.5M | -$8.8M |
| Net loss attributable to Nymox shareholders | -$4.3M | -$4.5M | -$8.8M |
| Basic and diluted loss per share | -$0.05 | -$0.05 | -$0.10 |
| Weighted average number of common shares outstanding | 96.0M shares | 93.7M shares | 91.7M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash | $6.0K | $74.0K | ||
| Other receivables | $22.0K | $27.0K | ||
| Security deposit | $36.0K | $36.0K | ||
| Prepaid assets | $11.0K | $16.0K | ||
| Bond Deposits | $500.0K | $500.0K | ||
| Total current assets | $575.0K | $653.0K | ||
| Property and equipment | $1.0K | $1.0K | ||
| Total assets | $576.0K | $654.0K | ||
| Accounts payable and accrued liabilities | $4.1M | $3.9M | ||
| Accounts payable to related parties | $55.0K | $27.0K | ||
| Accrued interest payable to related party | $659.0K | $219.0K | ||
| Advances, related Party | $5.1M | $3.3M | ||
| Total current liabilities | $9.9M | $7.4M | ||
| Total liabilities | $9.9M | $7.4M | ||
| Share capital - unlimited authorized shares at no par value 102,040 and 94,540 shares outstanding at December 31, 2025 and 2024, respectively | $173.9M | $173.9M | $173.8M | |
| Share capital payable | $272.0K | $3.8M | ||
| Additional paid-in capital | $33.3M | $28.0M | ||
| Accumulated deficit | -$216.7M | -$212.5M | ||
| Total Stockholders' equity (deficit) | -$9.3M | -$6.8M | -$3.2M | -$482.0K |
| Total liabilities and stockholders' equity | $576.0K | $654.0K | ||
| Number of shares outstanding | 102.0M shares | 94.5M shares | 93.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash | $6.0K | $74.0K | ||
| Other receivables | $22.0K | $27.0K | ||
| Security deposit | $36.0K | $36.0K | ||
| Prepaid assets | $11.0K | $16.0K | ||
| Bond Deposits | $500.0K | $500.0K | ||
| Total current assets | $575.0K | $653.0K | ||
| Property and equipment | $1.0K | $1.0K | ||
| Total assets | $576.0K | $654.0K | ||
| Accounts payable and accrued liabilities | $4.1M | $3.9M | ||
| Accounts payable to related parties | $55.0K | $27.0K | ||
| Accrued interest payable to related party | $659.0K | $219.0K | ||
| Advances, related Party | $5.1M | $3.3M | ||
| Total current liabilities | $9.9M | $7.4M | ||
| Total liabilities | $9.9M | $7.4M | ||
| Share capital - unlimited authorized shares at no par value 102,040 and 94,540 shares outstanding at December 31, 2025 and 2024, respectively | $173.9M | $173.9M | $173.8M | |
| Share capital payable | $272.0K | $3.8M | ||
| Additional paid-in capital | $33.3M | $28.0M | ||
| Accumulated deficit | -$216.7M | -$212.5M | ||
| Total Stockholders' equity (deficit) | -$9.3M | -$6.8M | -$3.2M | -$482.0K |
| Total liabilities and stockholders' equity | $576.0K | $654.0K | ||
| Number of shares outstanding | 102.0M shares | 94.5M shares | 93.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$4.3M | -$4.5M | -$8.8M |
| Loss on debt conversion | $0 | $0 | $440.0K |
| Depreciation | $1.0K | $1.0K | $11.0K |
| Stock-based compensation | $1.7M | $671.0K | $3.4M |
| Amortization and others | $125.0K | $0 | $158.0K |
| Other receivables | $5.0K | -$16.0K | -$1.0K |
| Bond Deposits | $0 | $0 | -$500.0K |
| Prepaid assets | $5.0K | -$8.0K | $0 |
| Accounts payable and accrued liabilities | $625.0K | $1.2M | $1.3M |
| Net cash used in operating activities | -$1.8M | -$2.6M | -$4.1M |
| Purchase of property and equipment | $1.0K | $0 | $3.0K |
| Net cash flows used in investing activities | -$1.0K | $0 | -$3.0K |
| Proceeds from the issuance of share capital and warrants | $0 | $0 | $1.1M |
| Borrowings on debt | $1.7M | $2.7M | $1.8M |
| Repayment of operating lease and financing obligation | $0 | $64.0K | $173.0K |
| Net cash provided from financing activities | $1.7M | $2.6M | $2.7M |
| Net (decrease) increase in cash | -$68.0K | $4.0K | -$1.3M |
| Income taxes paid | $0 | $0 | $0 |
| Interest paid | $0 | $0 | $0 |
| Conversion of note payable, related party, to equity | $0 | $0 | -$1.0M |
| Forgiveness of accrued and deferred salary1 | $0 | $0 | $206.0K |
| Equity component of convertible note | $37.0K | $219.0K | $0 |
| Exchange of accounts payable for notes payable | $0 | $150.0K | $0 |
No quarter-by-quarter statement was filed.
What it owns
What NYMOX PHARMACEUTICAL CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
Leadership
Who has led NYMOX PHARMACEUTICAL CORP, and when. Pick a name to see everywhere that person has worked.
- Chief executive officerPaul Averback Nov 6, 2018 to Nov 6, 20189
- Chief financial officerErik Danielsen Aug 23, 2016 to Jan 3, 201910
Board members and other officers (3)
- Board memberPaul Averback Nov 6, 2018 to Nov 6, 20189
- Board memberRandall J. Lanham Nov 6, 2018 to Nov 6, 201811
- General counselRandall J. Lanham Nov 6, 2018 to Nov 6, 201811
Timeline
- Nov 6, 2018New chief executive Paul Averback becomes CEO9
Filings
67 filings to the SEC since October 2021: 7 annual reports, 3 insider forms, 57 other. The latest 20:
- Sep 29, 202620-F/A EDGAR
- Sep 16, 202620-F/A EDGAR
- Sep 14, 202620-F EDGAR
- Aug 31, 20266-K EDGAR
- Aug 7, 20266-K EDGAR
- Jun 3, 20266-K EDGAR
- Mar 27, 20266-K EDGAR
- Nov 7, 20256-K EDGAR
- Oct 22, 20256-K EDGAR
- Oct 22, 20256-K EDGAR
- Sep 23, 20256-K EDGAR
- Jun 3, 202520-F EDGAR
- May 22, 20256-K EDGAR
- May 1, 2025NT 20-F FORM 20-F EDGAR
- Mar 11, 20256-K EDGAR
- Jan 2, 20256-K EDGAR
- Dec 17, 20246-K EDGAR
- Aug 29, 202420-F EDGAR
- Jul 18, 20246-K EDGAR
- Jul 16, 20246-K EDGAR
The 67 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 27, 2023 | Robinson James GeorgeDirector | Buy | 40,000 | $0.47 | $18.8K | Form 4 |
| Apr 25, 2023 | Robinson James GeorgeDirector | Buy | 40,000 | $0.45 | $18.0K | Form 4 |
| Apr 25, 2023 | Robinson James GeorgeDirector | Buy | 40,000 | $0.45 | $18.0K | Form 4 |
| May 2, 2022 | Robinson James GeorgeDirector | Buy | 1,151,515 | $1.65 | $1.9M | Form 4 |
From Forms 4 filed with the SEC.
SEC filer profile
How NYMOX PHARMACEUTICAL CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARNYMOX PHARMACEUTICAL CORP1
- CIK0001018735
- Filer statusAccelerated filer1
- Fiscal year endsDecember 311
- Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address9900 Cavendish Blvd., Suite 306, St. Laurent, Quebec Canada, A8 H4M 2V21
- Phone1-800-936-96691
- Shares outstanding102,040,140 as of Dec 31, 20258
- On EDGAR sinceAug 8, 19961
- Filings408 in all: 6-K (182), 4 (93), 20-F (29), UPLOAD (14), CORRESP (11), SC 13G/A (10), 20-F/A (8), 6-K/A (8)1
All 25 form types
20FR12G/A (6), F-3 (6), POS AM (6), 424B3 (5), 424B5 (5), EFFECT (5), SC 13G (5), F-3/A (3), 4/A (2), NT 20-F (2), SC 13D (2), 20FR12G (1), 25-NSE (1), 3 (1), CT ORDER (1), F-1 (1), F-1/A (1)
- Latest filingsAnnual report (20-F) Sep 14, 2026
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARRandall J. Lanham, Board member